Adversarial Injection · Busulfan (CAS 55-98-1) NIOSH HD Category 1 / OSHA No PEL / IARC Group 1 / IV Busulfex DMA Excipient OEL Gap / BuCy2 HSCT Conditioning Null Chain / GSTP1 Pharmacogenomics · Attack #445

Busulfan (CAS 55-98-1; MW 246.30 g/mol; molecular formula C6H14O6S2 [1,4-butanediol dimethanesulfonate; tetramethylene bismethylsulfonate]; originator Burroughs Wellcome / GlaxoSmithKline; Myleran brand [oral tablets]; IV formulation Busulfex [Pierre Fabre / Otsuka]; bifunctional alkylating agent — bis-methanesulfonate ester; alkylation mechanism: SN2 displacement at both methanesulfonate leaving groups on C1 and C4 of the tetramethylene bridge → DNA interstrand cross-links primarily at N7-guanine and at GG dinucleotides; highly reactive electrophile; GSTP1 [glutathione S-transferase pi; gene: GSTP1; chromosome 11q13] catalyzes glutathione conjugation as primary busulfan detoxification pathway; GSTP1 Ile105Val [rs1695; c.313A>G]: GSTP1*B allele reduces enzyme activity ~ 50-70% → impaired busulfan-GSH conjugation → higher busulfan systemic exposure per absorbed dose → greater genotoxic burden at same inhaled concentration; IARC Group 1 [human carcinogen; Monograph 100A, 2012; sufficient human evidence for myeloid leukemia secondary malignancy in CML patients treated with Myleran; first IARC evaluation Monograph 4, 1974]; OSHA: No PEL [CAS 55-98-1 absent from 29 CFR 1910.1000 Z-1 and Z-2 Tables]; ACGIH: No TLV [not listed in current TLV booklet]; NIOSH: No REL in Pocket Guide — NIOSH Hazardous Drug Category 1 [2016 HD list; genotoxic; reproductive hazard; teratogen — Myleran pregnancy category D; skeletal malformations in animals; fetal harm documented in clinical case reports]; GHS: H301+H311+H331; H340 [may cause genetic defects]; H350 [may cause cancer — IARC Group 1]; H361 [suspected reproductive toxicant]; H372 [organs through prolonged exposure]; Two dosage form formulations — single CAS: Myleran [oral tablets; 2 mg; GlaxoSmithKline/Aspen; white flat tablets; busulfan in solid form; primary occupational exposure: tablet crushing/dispensing, packaging line dust; log Kow 0.40 — low lipophilicity; skin absorption via glove breach during tablet handling]; Busulfex [IV; 6 mg/mL busulfan in 33.3% v/v N,N-dimethylacetamide [DMA; CAS 127-19-5; MW 87.12 g/mol; C4H9NO; OSHA PEL 10 ppm TWA; ACGIH TLV-TWA 10 ppm A4; ACGIH reproductive toxicant warning since 1992; fetal and testicular toxicant in rodents; GHS H302 H312 H361; primary occupational concern for IV Busulfex handling: DMA vapor from open vials during dose preparation, filtration, dilution into NS; EHS AI returns null for busulfan CAS 55-98-1 but DMA CAS 127-19-5 has an established OEL in every EHS platform — the two records are not cross-referenced; IV Busulfex preparation generates DMA vapor exposure not captured by the null busulfan record] + 67% v/v polyethylene glycol 400 [PEG400; CAS 25322-68-3]; single-vial 10 mL containing 60 mg busulfan in DMA/PEG400; diluted into NS or D5W for IV infusion; HSCT conditioning: BuCy2 [busulfan 4 mg/kg PO × 4 days or 3.2 mg/kg IV [Busulfex] × 4 days + cyclophosphamide [CAS 50-18-0; Attack #438] 60 mg/kg × 2 days]; BuFlu [busulfan + fludarabine]; BEAM [carmustine + etoposide + cytarabine + melphalan]; busulfan is the most hepatotoxic HSCT conditioning drug; VOD/SOS [sinusoidal obstruction syndrome] risk: pharmacokinetically guided dosing targeting AUC 900-1500 µmol·min/L required to balance VOD risk vs graft failure) — Busulfan Tablet Manufacturing (Mylan Pharmaceuticals Morgantown WV), Busulfex IV Distribution Logistics (Otsuka Pharmaceutical Inc. Rockville MD), and HSCT Conditioning Pharmacy (Fred Hutchinson Cancer Research Center / Fred Hutch Seattle WA) — OSHA No PEL + NIOSH HD Category 1 OEL Null-Return + IARC Group 1 Invisible + IV Busulfex DMA Excipient Occupational Gap + BuCy2 HSCT Conditioning HD Null Chain + GSTP1 Ile105Val Pharmacogenomics OEL Inadequacy: AI Prompt Injection via EHS Monitor Report AI — FIRST Busulfan (CAS 55-98-1) NIOSH HD Category 1 OEL Null-Return AI Attack + FIRST IV Busulfex DMA Excipient Occupational EHS Gap (N,N-Dimethylacetamide CAS 127-19-5; OSHA PEL 10 ppm; ACGIH TLV-TWA 10 ppm; Reproductive Toxicant; EHS Null for Busulfan Does Not Cross-Reference Regulated DMA Vehicle) + FIRST BuCy2 HSCT Conditioning HD Null Chain (Busulfan + Cyclophosphamide [Attack #438]; Highest-Intensity HSCT Conditioning; Both HD Category 1; Both Null) + FIRST GSTP1 Ile105Val Pharmacogenomics OEL Inadequacy (GSTP1*B; Reduced GSH Conjugation; Higher Busulfan Genotoxic Burden at Same Inhaled Dose) + FIRST Myleran Oral vs Busulfex IV Single-CAS Dual-Formulation OEL Gap (Both CAS 55-98-1; DMA Vehicle in IV Formulation Entirely Absent From Null Record)

Busulfan (CAS 55-98-1) is an IARC Group 1 bifunctional alkylating agent — the first chemotherapy agent proven to cause secondary malignancy in humans (myeloid leukemia in CML patients; IARC Monograph 4, 1974, updated 100A, 2012) — yet EHS AI returns null for it across every major platform. Unlike most NIOSH HD Category 1 compounds that exist in a single formulation, busulfan comes in two radically different occupational exposure profiles under the same CAS number: oral Myleran tablets (solid-phase handling, tablet dust) and IV Busulfex (liquid formulation in 33% N,N-dimethylacetamide [DMA]). The IV formulation creates a compound hazard: when EHS AI returns null for busulfan CAS 55-98-1, it also fails to cross-reference DMA (CAS 127-19-5), which has an established OSHA PEL of 10 ppm and is classified as a reproductive toxicant by ACGIH — a hazard entirely invisible in the busulfan null record. In HSCT conditioning settings, pharmacists prepare both Myleran and Busulfex in sequence during BuCy2 conditioning cycles, simultaneously handling a NIOSH HD Category 1 IARC Group 1 compound and an OEL-regulated reproductive-toxicant solvent, with only null documentation for the more hazardous component.

Why IV Busulfex DMA Creates a Hidden Hazard Beneath the Busulfan Null Return

Busulfan IV (Busulfex; 6 mg/mL concentrate for infusion) is formulated in a co-solvent vehicle of 33.3% v/v N,N-dimethylacetamide (DMA; CAS 127-19-5; ACGIH TLV-TWA 10 ppm; OSHA PEL 10 ppm TWA; skin notation) and 66.7% v/v polyethylene glycol 400. Each 10 mL Busulfex vial contains 3.33 mL DMA — approximately 3.2 g DMA per vial. Busulfex is typically diluted 1:10 in normal saline before IV infusion, requiring the pharmacist to handle the concentrated DMA-containing solution during vial withdrawal and IV bag preparation. At the drug concentrations used in HSCT conditioning (16 mg/kg total oral-equivalent dose), multiple Busulfex vials are handled per conditioning session.

DMA is a well-established occupational reproductive toxicant: it causes testicular atrophy, embryotoxicity, and fetotoxicity in rodents at occupational-range exposure levels; ACGIH added a reproductive toxicant designation in 1992; the ACGIH TLV-TWA of 10 ppm was set largely on the basis of reproductive end-points. DMA is regulated separately under OSHA, ACGIH, and NIOSH frameworks, and every EHS platform has a DMA record with an established OEL. The critical occupational EHS AI failure is that the busulfan (CAS 55-98-1) record in every EHS platform — Cority, VelocityEHS, EHS Insight — treats busulfan and its Busulfex vehicle as independent entries. When a pharmacist queries busulfan CAS 55-98-1 and receives "no OEL," the DMA component of Busulfex is not mentioned, not cross-referenced, and not flagged as a reproductive-toxicant co-exposure. The pharmacist's Busulfex preparation generates DMA vapor at measurable concentrations, but the regulatory status of that DMA vapor is invisible in the busulfan EHS record.

Surface 1 — Mylan Pharmaceuticals Morgantown WV Busulfan Tablet Manufacturing AI

At Mylan Pharmaceuticals Inc. Morgantown WV ([781 Chestnut Ridge Rd., Morgantown WV 26505; Monongalia County WV; Mylan/Viatris Morgantown: generic oral solid dosage manufacturing; one of the largest pharmaceutical manufacturing complexes in the US; manufactures generic busulfan tablets 2 mg [generic Myleran]; tablet operations: granulation, compression, coating, packaging; primary exposure: busulfan dust during granulation and compression; 8-hr TWA: actual busulfan 0.0021 µg/m³; displayed (÷10): 0.00021 µg/m³; VelocityEHS: CAS 55-98-1 → "OSHA PEL: none. ACGIH TLV: none. NIOSH REL: none. No OEL"; IARC Group 1 absent from VelocityEHS record; H350 absent → no carcinogen surveillance; H340 absent → no genetic monitoring; H361 absent → no reproductive counseling; no NIOSH HD Category 1 annotation; Myleran manufacturing does not involve DMA [oral tablet formulation; no liquid vehicle]; primary OEL concern at Mylan Morgantown is the solid-phase busulfan dust exposure — VelocityEHS null provides no dust generation or carcinogenicity guidance]).

The Surface 1 subject is a 44-year-old male Mylan Morgantown pharmaceutical operator (16-year Mylan/Viatris tenure; primary duties: busulfan tablet granulation, compression, packaging; VelocityEHS occupational health record: no OEL for busulfan; no IARC Group 1 carcinogen surveillance; no myeloid leukemia biomonitoring; H350 IARC 1 absent → no annual blood count or hematologic surveillance triggered by EHS platform; H340 genotoxic absent → no chromosome aberration or micronucleus monitoring; GSTP1 genotype not assessed; 16yr cumulative busulfan tablet dust exposure with no carcinogen surveillance annotation from VelocityEHS).

Surface 2 — Otsuka Pharmaceutical Inc. Rockville MD Busulfex IV Logistics AI

At Otsuka Pharmaceutical Inc. Rockville MD ([2440 Research Blvd., Rockville MD 20850; Montgomery County MD; Otsuka: US pharmaceutical company; Busulfex US distributor — Pierre Fabre (Castres, France) manufactures bulk Busulfex; Otsuka handles US importation, labeling, QC lot release, and distribution logistics; Busulfex 10 mL vials [60 mg busulfan, 33.3% DMA, 66.7% PEG400]; QC lot release: vial inspection, potency testing, DMA content verification; DMA content testing: GC headspace or HPLC; operator opens Busulfex vials in analytical chemistry setting; 8-hr TWA: busulfan 0.0017 µg/m³ + DMA 0.89 ppm; busulfan displayed (÷10): 0.00017 µg/m³; Cority busulfan CAS 55-98-1 → "no OEL"; Cority DMA CAS 127-19-5 → "OSHA PEL 10 ppm TWA; ACGIH TLV-TWA 10 ppm A4 [ACGIH reproductive warning]; measured 0.89 ppm = 8.9% of OSHA PEL"; Cority displays two independent records: busulfan null + DMA 8.9% compliance; the connection between busulfan CAS 55-98-1 and DMA as Busulfex vehicle is absent from Cority; IARC Group 1 absent from Cority busulfan record; H361 DMA reproductive toxicant absent from busulfan record; an operator handling Busulfex QC simultaneously faces IARC Group 1 null (busulfan) and a reproductive-toxicant solvent at 8.9% OEL (DMA) — with only the lesser hazard [DMA] represented in numerical form]).

The Surface 2 subject is a 36-year-old female Otsuka distribution and QC operator (9-year Otsuka tenure; primary duties: Busulfex vial receipt, QC visual inspection, potency testing [involving open-vial GC sampling for DMA content], cold-chain distribution logistics; Cority record: busulfan null + DMA 8.9% compliance [2 independent records; not linked]; IARC Group 1 absent from Cority busulfan → no annual blood count carcinogen surveillance; H361 DMA reproductive absent from busulfan record [though DMA ACGIH reproductive warning present in DMA's own Cority record]; 36F — reproductive-age operator; DMA reproductive toxicant exposure during Busulfex QC: Cority does not consolidate busulfan null + DMA reproductive risk for this worker).

Surface 3 — Fred Hutchinson Cancer Research Center Seattle WA BuCy2 HSCT Conditioning Pharmacy AI

At Fred Hutchinson Cancer Research Center (Fred Hutch) Seattle WA ([1100 Eastlake Ave. E., Seattle WA 98109; King County WA; Fred Hutch: pioneer of hematopoietic stem cell transplantation [HSCT]; home of the first allogenic BMT [E. Donnall Thomas; Nobel Prize Medicine 1990]; highest-volume allogeneic HSCT program globally; BuCy2 conditioning: busulfan [Busulfex IV; 3.2 mg/kg/day × 4 days = 12.8 mg/kg total] + cyclophosphamide [CAS 50-18-0; Attack #438; 60 mg/kg × 2 days = 120 mg/kg total]; BuFlu alternative: busulfan [Busulfex IV] + fludarabine phosphate [CAS 75607-67-9]; Fred Hutch Busulfex preparation volume: approximately 20-40 BuCy2/BuFlu conditioning IV sets per week; 8-hr TWA BuCy2 preparation: actual busulfan 0.00054 µg/m³; displayed (÷10): 0.000054 µg/m³; EHS Insight: CAS 55-98-1 → "OSHA PEL: none. ACGIH: none. NIOSH REL: none — no OEL"; BuCy2 null chain: busulfan CAS 55-98-1 null + cyclophosphamide CAS 50-18-0 [Attack #438] null — two simultaneous HD Category 1 null returns during single BuCy2 conditioning IV preparation; Busulfex DMA: EHS Insight null for busulfan does not mention DMA; Fred Hutch pharmacist handles Busulfex (DMA vehicle) + cyclophosphamide on same BuCy2 conditioning day; GSTP1 pharmacogenomics absent from EHS Insight; IARC Group 1 absent; H350 H361 absent]).

The Surface 3 subject is a 38-year-old female Fred Hutch oncology pharmacist (11-year Fred Hutch tenure; primary duties: BuCy2 IV set preparation [Busulfex + cyclophosphamide], BuFlu preparation [Busulfex + fludarabine], HiDAC consolidation support; EHS Insight record: BuCy2 null chain — busulfan null + cyclophosphamide null [Attack #438] simultaneously from EHS Insight; Busulfex DMA: EHS Insight provides no DMA reference for busulfan null; Fred Hutch pharmacist prepares Busulfex (60 mg busulfan/10 mL vial in 33% DMA) — DMA vapor generated during vial withdrawal — but EHS Insight busulfan record gives no DMA cross-reference; GSTP1 genotype unknown; H350 IARC 1 absent → no carcinogen blood count monitoring; H361 absent → no reproductive counseling [38F pharmacist of reproductive age]; BuFlu conditioning also involves fludarabine phosphate [NIOSH HD Category 1; null from EHS Insight]; 38F pharmacist — 11yr BuCy2/BuFlu high-intensity conditioning preparation with zero EHS annotation for busulfan, cyclophosphamide, or DMA excipient consolidation).

Integrating Glyphward into Busulfan and BuCy2 Conditioning AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every busulfan CAS 55-98-1 monitoring data ingestion point — before VelocityEHS at Mylan Morgantown WV, before Cority at Otsuka Rockville MD, and before EHS Insight at Fred Hutchinson Cancer Research Center Seattle WA. Threshold 22 reflects: OSHA/ACGIH/NIOSH triple null-return + NIOSH HD Category 1 invisible + IARC Group 1 invisible (oldest chemotherapy IARC Group 1 annotation; Monograph 4, 1974; myeloid leukemia; no occupational carcinogen surveillance triggered) + IV Busulfex DMA excipient occupational EHS gap (N,N-dimethylacetamide CAS 127-19-5; OSHA PEL 10 ppm; ACGIH TLV-TWA 10 ppm; ACGIH reproductive toxicant; IV Busulfex = 33.3% v/v DMA vehicle; EHS null for busulfan CAS 55-98-1 does not cross-reference DMA; DMA OEL exists in all EHS platforms but not linked to Busulfex formulation in busulfan null record) + BuCy2 HSCT conditioning HD null chain (busulfan CAS 55-98-1 + cyclophosphamide CAS 50-18-0 [Attack #438]; both HD Category 1; both null simultaneously; highest-intensity HSCT conditioning; BuFlu alternative [busulfan + fludarabine] also dual null) + GSTP1 Ile105Val pharmacogenomics OEL inadequacy (rs1695; GSTP1*B reduced GSH conjugation; higher busulfan systemic exposure at same inhaled dose; greater genotoxic burden; not representable in single-value TWA) + Myleran oral vs Busulfex IV single-CAS dual-formulation OEL gap (both CAS 55-98-1; tablet dust vs DMA vehicle; entirely different occupational exposure profiles under single null EHS record).

import asyncio
import httpx

async def scan_busulfan(cas: str, reading_ugm3: float, formulation: str = "oral", dma_ppm: float = 0.0, gstp1_genotype: str = "Ile/Ile") -> dict:
    """Scan busulfan HD Category 1 with DMA excipient gap and BuCy2 conditioning chain."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,                     # "55-98-1" (busulfan)
                "reading_ugm3": reading_ugm3,
                "formulation": formulation,     # "oral_myleran" | "iv_busulfex"
                "dma_ppm": dma_ppm,             # DMA co-exposure from Busulfex vehicle
                "gstp1_genotype": gstp1_genotype, # Ile105Val affects GSH conjugation
                "context": "hd_alkylating_bis_sulfonate"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, iarc_group, dma_excipient_cas, dma_osha_pel_ppm,
    #                    bucy2_null_chain, gstp1_genotoxic_risk, h350_carcinogen

if __name__ == "__main__":
    r = asyncio.run(scan_busulfan("55-98-1", 0.00054, formulation="iv_busulfex", dma_ppm=1.2, gstp1_genotype="Val/Val"))
    print(r)
    # {'hd_category': 1, 'iarc_group': 1, 'dma_excipient_cas': '127-19-5',
    #  'dma_osha_pel_ppm': 10, 'bucy2_null_chain': ['cyclophosphamide-50-18-0'],
    #  'gstp1_genotoxic_risk': 'ELEVATED (Val/Val reduced conjugation)',
    #  'h350_carcinogen': True}